EP 208: Gene therapy at a crossroads: Successes, concerns, and the path forward

Om avsnittet

Summary:

This week on The Genetics Podcast, Patrick Short takes a solo deep dive into the current state of gene therapy ahead of next week’s live recording at ASHG. He explores the promise and limitations of adeno-associated virus (AAV) delivery, examples of gene therapies for neuromuscular diseases, and the challenges of balancing safety, cost, and commercial viability in rare diseases.

Show Notes:

0:00 Intro to The Genetics Podcast

00:59 Episode overview

02:50 Definition and scope of gene therapy

04:50 Gene therapy delivery via adeno-associated virus (AAV) and associated challenges and advantages

06:40 AAV-based gene therapy and other advanced therapies in spinal muscular atrophy (SMA)

10:29 Recent safety concerns around Sarepta Therapeutics’ AAV-based gene therapy for Duchenne muscular dystrophy (DMD)

19:30 Commercial viability challenges for rare disease gene therapy

24:26 Risk-benefit analysis of gene therapy for rare diseases

28:33 Considerations for optimizing AAV design and delivery routes

31:26 Alternative approaches for delivery using viral and non-viral methods

36:09 The future of AAV gene therapy

41:42 Closing remarks

Find out more

Update on Sarepta Therapeutics’ gene therapy for DMD (https://www.fiercepharma.com/pharma/sarepta-shares-more-elevidys-safety-data-response-patient-group-fda-petition)

Please consider rating and reviewing us on your chosen podcast listening platform!

https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

Om avsnittet

Fler avsnitt

EP 257: Managing hereditary cancer risk and medical uncertainty with Marleah Dean Kruzel of the University of South Florida

EP 256: Cutting through the AI hype in drug discovery with Dave Hallett of Recursion

EP 255: Turning long-read sequencing into a routine part of clinical care with Danny Miller of the University of Washington

EP 254: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent Richards of 5 Prime Sciences

EP 253: The genetics of brain size, growth, and aging with Andrew Jackson of the University of Edinburgh

EP 252: The diagnosis that became a mission to cure rare disease: Advancing genetic medicine using AI with Stevie Ringel of Nome

EP 251: Cracking the delivery barrier in genetic medicine with Jagesh Shah of Mirai Bio

EP 250: Redefining rare disease realities with Sharon Terry of the Genetic Alliance [Re-run]

EP 249: Building the world's most detailed genetic map of inflammatory bowel disease with Carl Anderson of the Wellcome Sanger Institute

EP 248: The blood mutations rewriting cardiovascular risk: Clonal hematopoiesis and polygenic risk with Pradeep Natarajan of Massachusetts General Hospital